Dual Tyrosyl-DNA Phosphodiesterase/Topoisomerase Inibitors
- Summary
- Purdue University researchers have developed a series of novel, low molecular-weight compounds that can act as dual inhibitors of both TOP1 and TDP1. A dual inhibitor of this type would offer significant advantages over individual TOP1 and TDP1inhibitors alone such as simplification of delivery and bioavailability. In lab tests, the dual inhibitor is an equally potent TOP1 inhibitor as the commercially available camptothecin. These molecules are thought to function by stalling the DNA synthesis phase of the cell cycle, thereby inducing apoptosis, and effectively killing the cell. This drug could work in combination with other chemotherapies to effectively eliminate highly proliferative cell growth in the body.
- Technology Benefits
- First dual inhibitor of TOP1 and TDP1Shown to be as cytotoxic to TOP1 as camptothecinA potentially more potent chemotherapy agent
- Technology Application
- Cancer TreatmentMedical/HealthcarePharmaceuticals
- Detailed Technology Description
- Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
- Countries
- United States
- Application No.
- 8,912,213
- *Abstract
-
- *Background
- Topoisomerase 1 (TOP1) is an enzyme involved in the replication of DNA. Molecules displaying TOP1 inhibitory function have found clinical applications as well as the frequent subject of research. Another enzyme functioning alongside TOP1 is tyrosyl-DNA phosphodiesterase 1 (TDP1), which repairs DNA lesions. Observations of this enzyme suggest mediating its activity could potentiate the cytotoxic effect of TOP1 inhibitors. TDP1 inhibitory activity has been seen to a limited extent in a handful of compounds, though their potencies, specificities, and pharmacokinetic properties leave much to be desired.
- *IP Issue Date
- Dec 16, 2014
- *IP Type
- Utility
- *Stage of Development
- Proof of Concept
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipMark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
- Country/Region
- USA
For more information, please click Here
